RBC Capital Markets analysts believe key programs, such as Golden Dome and space communications and operations, will continue to support the recent strength in the defense tech stocks.
In a research note published on Thursday, the analysts stated they continue to favor Karman Space & Defense (NYSE: KRMN), AeroVironment (NASDAQ:AVAV) Inc, and Kratos Defense & Security Solutions Inc (NASDAQ: KTOS) in the space.
Shares in Seeing Machines Ltd (AIM:SEE, OTC:SEEMF) rose 4% at 2.54p on Thursday after the tech firm's prelims and outlook statement reassured the market.
In their wake, Peel Hunt reiterated its 'buy' rating and 3p target price, saying the group’s automotive business remains the key growth driver ahead of next year’s European driver-monitoring deadline
Tiziana Life Sciences Ltd (NASDAQ:TLSA) shares rose more than 10% in late morning trading on Thursday after the biotech company said it plans to advance development of TZLS-501, an antibody that blocks a key inflammatory pathway.
Tiziana noted that the therapy targets the interleukin-6 receptor, or IL-6R.
Gunnison Copper Corp (TSX:GCU, OTCQB:GCUMF) shares gained more than 10% in late-morning trading on Thursday after the multi-asset, pure-play copper developer and producer reported its first copper cathode sales from the fully operational Johnson Camp Mine in Arizona.
The initial sale totalled 225,371 pounds, generating gross proceeds of about US$1.05 million at an average price of US$4.64 per pound.
T Stamp Inc, doing business as Trust Stamp Inc (NASDAQ:IDAI, EURONEXT:AIID), announced that it has reached 100 financial institutions on its low-code Orchestration Layer.
The company also reported that it has executed a contract amendment with its flagship Fortune 500 financial services customer, extending the contract term to May 2031 with minimum gross revenue exceeding $12.7 million over the balance of the term.
Tiziana Life Sciences Ltd (NASDAQ:TLSA) said Thursday it plans to advance development of TZLS-501, an antibody that blocks a key inflammatory pathway, at a time when big drugmakers are paying closer attention to the area.
The Boston-based biotech said the therapy targets the interleukin-6 receptor, or IL-6R.
Immunic Inc (NASDAQ:IMUX) has presented clinical trial data suggesting its oral therapy, vidofludimus calcium, could help slow disability in patients with progressive multiple sclerosis, a form of the disease that remains difficult to treat.
The results were shared at the annual congress of the European Committee for Treatment and Research in Multiple Sclerosis in Barcelona, one of the largest gatherings of neurologists and researchers in the field.
Algernon Health (CSE:AGN, OTCQB:AGNPF) told investors it has signed a C$4 million equipment order and financing agreement to acquire brain scanning systems that will be used in Algernon’s planned neuroimaging centres, which will be focused on early-stage Alzheimer’s detection.
The agreement is with Catalyst MedTech to deploy four Oncovision CareMiBrain PET scanner systems at new clinics across the United States.
Gunnison Copper Corp (TSX:GCU, OTCQB:GCUMF) has reported its first copper cathode sales from the fully operational Johnson Camp Mine in southeast Arizona.
The initial sale totalled 225,371 pounds, generating gross proceeds of approximately US$1.05 million at an average price of US$4.64 per pound.
Poolbeg Pharma PLC (AIM:POLB, OTC:POLBF) shares climbed as much as 20% in morning trading after the company secured a partner to run its next cancer trial and lined up free supply of a key therapy.
The London-listed biotech said Accelerating Clinical Trials (ACT), a UK-based blood cancer trials specialist, will oversee its Phase IIa study of POLB 001, an experimental drug aimed at reducing dangerous side effects from immunotherapies.
Anglo Asian Mining Plc (LSE:AAZ, OTC:AGXKF) reported a return to profitability in its interim results for the first six months of 2025, as two new mines entered production.
The Azerbaijani gold and copper miner posted a pre-tax profit of $7.1 million, compared to a $5.5 million loss in H1 2024, as revenue more than tripled to $40.9 million, supported by higher production volumes and strong commodity prices.
Polarean Imaging PLC (AIM:POLX, OTC:PLLWF) lowered its revenue outlook for 2025 after cuts to US medical research and hospital funding delayed purchasing decisions for its lung imaging systems.
However, it provided a more upbeat, longer-term commercial assessment of demand for its xenon-based MRI technology.
Poolbeg Pharma PLC (AIM:POLB, OTC:POLBF) has lined up a specialist clinical trials partner and secured free supply of a key drug for its upcoming study of POLB 001, an experimental treatment designed to make cancer immunotherapy safer.
The London-listed biotech said Thursday it has appointed Accelerating Clinical Trials (ACT), a UK-based blood cancer trials organisation, to run its phase IIa study.
Chariot Ltd (AIM:CHAR, OTC:OIGLF) has reported interim results that outlined its refocused strategy as it split the business into two standalone units, Upstream Oil & Gas and Renewable Power.
The group remained debt-free in the period and had a cash balance of US$5.6 million at the 30 June half-year stage after a gross $7.1 million was raised earlier that month.
Seeing Machines Ltd (AIM:SEE, OTC:SEEMF) expects to hit cashflow break-even by the end of 2025 and turn cash positive in the second half of its new financial year, as demand builds ahead of a European safety regulation that will require all new cars to carry driver-monitoring cameras.
The technology company, listed in London, makes artificial intelligence-powered systems that track driver attention and fatigue.
Petra Capital has initiated coverage of Kairos Minerals Ltd (ASX:KAI, OTCQB:KAIFF) with a Buy rating and a target price of A$0.05, highlighting the company’s Mt York Gold Project in Western Australia’s Pilbara as an emerging development with strong growth potential.
Kairos shares have already seen a 55% gain over the past month, rising from A$0.02 on September 11 to A$0.031 today, though Petra sees potential for further upside.
Recce Pharmaceuticals Ltd (ASX:RCE, OTC:RECEF) has begun patient dosing in its registrational Phase 3 clinical trial of RECCE® 327 Topical Gel (R327G) for diabetic foot infections (DFI) in Indonesia, marking a major step towards potential commercialisation of its lead anti-infective.
Five clinical study sites have now been activated, with enrolment under way for up to 310 patients who will receive either R327G or placebo. The trial’s primary endpoint is clinical response based on the FDA-recognised Lipsky Scale, with secondary measures including total wound score and safety.
Resolution Minerals Ltd (ASX:RML, OTC:RLMLF) has secured approval to double the scale of its current drill campaign at the Horse Heaven gold-antimony-tungsten-silver project in Idaho, while also expanding its landholding by a further 600 acres.
The US Forest Service has granted an amendment to Resolution’s Plan of Operation, enabling the company to extend its Phase 1 drilling season by an additional month beyond the scheduled end date of September 30. The extension will allow Resolution to add 8–10 extra holes to the program, taking the total to 18–20 holes for about 18,000 feet (5,490 metres) of drilling.
American Uranium Ltd (ASX:AMU, OTC:GTRIF) has received regulatory approval to commence its resource expansion and infill drilling campaign at the Lo Herma Project in Wyoming, one of the few near-term in-situ recovery (ISR) uranium projects in the United States.
The Land Quality Division of Wyoming’s Department of Environmental Quality has signed off on the program, with phase-one drilling expected to kick off in the fourth quarter of 2025.